These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19785066)

  • 1. Adoptive T-cell therapy of cancer.
    Erbayraktar Z
    J BUON; 2009 Sep; 14 Suppl 1():S193-201. PubMed ID: 19785066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
    Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
    Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive T-cell immunotherapy of cancer.
    Li Q; Chang AE
    Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
    Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
    Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy of cancer.
    Yee C
    Hematol Oncol Clin North Am; 2006 Jun; 20(3):711-33. PubMed ID: 16762731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA; Shu S; Chou T; Perry-Lalley D; Chang AE
    J Immunol; 1988 Aug; 141(3):1047-53. PubMed ID: 3260908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
    Inoue M; Plautz GE; Shu S
    Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
    Porter DL; June CH
    Bone Marrow Transplant; 2005 May; 35(10):935-42. PubMed ID: 15806121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of T-lymphocyte immunotherapy for the treatment of malignant disease.
    Thomas AK; June CH
    Cancer J; 2001; 7 Suppl 2():S67-75. PubMed ID: 11777267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive-cell-transfer therapy for the treatment of patients with cancer.
    Dudley ME; Rosenberg SA
    Nat Rev Cancer; 2003 Sep; 3(9):666-75. PubMed ID: 12951585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
    Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
    Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer.
    Kieback E; Charo J; Sommermeyer D; Blankenstein T; Uckert W
    Proc Natl Acad Sci U S A; 2008 Jan; 105(2):623-8. PubMed ID: 18182487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic redirection of T cells for cancer therapy.
    Westwood JA; Kershaw MH
    J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive therapy using antigen-specific T-cell clones.
    Yee C
    Cancer J; 2010; 16(4):367-73. PubMed ID: 20693849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
    Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
    Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 1 CD8+ T cells are superior to type 2 CD8+ T cells in tumor immunotherapy due to their efficient cytotoxicity, prolonged survival and type 1 immune modulation.
    Ye Z; Tang C; Xu S; Zhang B; Zhang X; Moyana T; Yang J; Xiang J
    Cell Mol Immunol; 2007 Aug; 4(4):277-85. PubMed ID: 17764618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.